Recruiting
Phase 2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Sponsor:

Ruth O'Regan

Code:

NCT04886531

Conditions

Breast Cancer

HER2-positive Breast Cancer

ER Positive Breast Cancer

PR-Positive Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Neratinib

Letrozole (L) or Anastrozole (A)

Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information